Duchenne UK is investing £543,314 to fund 5 posts at the John Walton Muscular Dystrophy Research Centre and Royal Victoria Infirmary in Newcastle

Alex and Emily went to Newcastle to see the newly refurbished Clinical Research Facility.Read more

DUCHENNE INFORMATION DAY: PLEASE SAVE THE DATE

Duchenne UK is hosting its first Duchenne Information Day in the North West. We’re hosting it in collaboration with Alder Hey Children's Hospital, the National Institute for Health Research Alder Hey Clinical Research Facility, the DMD Hub and TREAT-NMD.Read more

Duchenne UK announces new digital innovation funding as part of commitment to supporting clinical trial development

Duchenne UK will fund the development of digital technology to develop and evaluate new approaches to measuring efficacy and safety in clinical trialsRead more

Duchenne UK grants £10,000 to support young people and their families living with Duchenne Muscular Dystrophy

With the funding from Duchenne UK, Decipha will work face to face with families and offer valuable support.Read more

Mumsnet Campaign: Join us to End Duchenne

Duchenne UK and Robyn feature as mumsnet.com's Guest Campaign for April. Robyn describes the life-changing moment when she heard her son's Duchenne diagnosis.Read more

Solid Biosciences Raises up to $50 Million in Series C Financing

We're delighted to share news that Solid Biosciences has raised $50million in new financing round. The money will progress the company’s DMD portfolio.Read more

Summit Utrophin Update

Summit Therapeutics Plc has provided Duchenne UK with a synopsis of the clinical update on their progress with the utrophin modulation program. PhaseOut DMD is a Phase 2 clinical trial evaluating ezutromid in patients with DMD.Read more

Summit Therapeutics announces that planned extension phase of their PhaseOut trial, will go ahead.

Summit are going to continue their planned extension of the PhaseOut DMD study.Read more

Swapping sectors is good….

On International Women's Day we would like to share a blog written by Fiona Lawrence, our Director of Research and Clinical Development. Fiona takes a look back at her year with Duchenne UK.Read more

A Call To Action

The European Medicines Agency wants to know about your direct experiences with Duchenne, and what the impact of having access to Exondys 51 may have on you and your family. Read our guide to submitting patient input.Read more

Rare Disease Day 2017

Today is Rare Disease Day, it takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients' lives.Read more